eXoZymes (Nasdaq: EXOZ)

As seen on Fox Business Network today, Chief Strategist at the Basenese Group, Lou Basenese, stated on eXoZymes' addressable market: "I mean, this sounds ridiculous, but it's in the trillions of market, I mean, trillions of dollars. And that's backed by McKinsey & Company - they did a study about six or seven years ago on the economic impact of synthetic biology type technologies. Like I mentioned earlier, it impacts everything we're doing everyday life. If you look around the products that you're using, whether it's things you're consuming or they're on your desk in electronics, there's some petroleum based process or chemical in there. So I really believe the opportunities are limitless." Full transcript from the New To The Street interview at the NYSE available here: https://lnkd.in/dx8yRfPC #exozymes #exozyme #enzymes #enzyme #synbio #syntheticbiology

As seen on Fox Business Network last week: "Our focus, especially in the beginning will be nutraceuticals that has pharmaceutical potential. What that means is basically nature have provided humankind with a lot of things over the years. And we are basically taking things to typically isolate from somewhere in nature. And we then mass manufacture that in the sustainable way. So it means a number of the things that is added to food, or taking as supplements, that's the nutraceutical angle of it. So that's the first market. And we can go to market with that right away. But some of these compounds, if especially done with the purity grades that we can do, can actually become pharmaceuticals, basically drugs. That's obviously a much longer journey with a FDA approval and partnerships via the clinical realities of that. And because they take longer and it takes often a partner for us, that's kind of why we talk about it as nutraceuticals with a pharmaceutical potential." - states our CEO, Michael Heltzen, during the New To The Street interview recorded at NYSE. #exozymes

What's the potential impact of exozymes? Bigger than the invention of the transistor? "So if I look back to when my dad was born, that's around the time that the invention of the transistor happened. I promise you, back then, almost nobody understood the impact that that would have on the present we're living in today. Back then, people were not thinking, wow, the transistor, that's going to do a lot of good things for me. Most people didn't hear about it. If they heard about it, they didn't care about it because they thought it had nothing to do with them. And look at us now. What the computer, what the internet, what the digital world has done for the world. Comparing exozymes to the transistor, this is a more fundamental breakthrough. It means it can have more impact." says CEO of eXoZymes (Nasdaq: EXOZ), Michael Heltzen If you're interested in learning more about the company and the history, take a look here: https://exozymes.com/about #exozymes

Congratulations to eXoZymes (Nasdaq: EXOZ) on their recent Nasdaq listing and today's bell ringing. Thanks for inviting Messaginglab Erum Azeez Khan and I to celebrate with you last night. Exozymes' vision is powerful: rapidly designing and engineering enzymes using AI and lab automation to create valuable compounds without cells. It's a sustainable approach to biochemical production that could transform how we make the products humanity needs. Keep up the great work! Alejandro Schmieder and Zachary Karl, Ph.D. you were sorely missed. #Biotech #Sustainability #Innovation #SyntheticBiology #enzymes

Experiencing the closing bell at Nasdaq this Wednesday was a fantastic experience, but we're already back to business as usual. Working on upcoming milestones that we look forward to sharing, once we're ready! This footage from CNBC was part of the coverage of our closing bell ceremony on Feb 19, 2025. (Credit: CNBC & Nasdaq, Inc.) #exozymes

This is Michael Heltzen's (CEO of eXoZymes) closing bell speech from February 19, 2025, when eXoZymes (Nasdaq: EXOZ) rang the closing bell at Nasdaq in New York. Heltzen, states: "I want to bring the attention to that?this is the beginning of a long journey.?It's a thing where we are going to have to have?partners and collaborators help out.?This is not a technology breakthrough?that we are going to keep to ourselves. We want to share it.?We want to share it with all of the world.?And with that,?please come join us,?help us,?support us,?at least follow us so we can have a conversation about how the future?can be a more sustainable future while still having the good life." Watch the full closing bell ceremony here https://lnkd.in/gx8FzVAq #exozymes Credit: Nasdaq, Inc.

?? Enzymes x AI = exozymes. ?? eXoZymes (Nasdaq: EXOZ) is pioneering AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines and biofuels. ?? Keep innovating, $EXOZ!

At 1PM Pacific today - February 19, 2025 - eXoZymes CEO Michael Heltzen will be joined by team members to ring the Nasdaq closing bell. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024. “Our team is thrilled to be ringing the closing bell to commemorate both our initial public offering and our significant progress towards establishing that after synthetic biology (SynBio) we're now entering the exozymes era of biotechnology,” said CEO of eXoZymes (Nasdaq: EXOZ), Michael Heltzen. “We appreciate the continued support of all our stakeholders and look forward to sharing our commercial milestones soon, as we unleash the power of our platform to rapidly transform affordable and widely available feedstocks into a diverse range of valuable chemicals at industrial scale.” The Nasdaq closing bell ceremony will be broadcast live starting at 12:50 PM Pacific Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit: https://lnkd.in/eJz78vY? https://lnkd.in/dRGB5-H9 #exozymes #nasdaq #IPO

What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain it in less than five minutes. #exozymes

Great article from Genetic Engineering & Biotechnology News capturing the essence of our introduction of exozymes. "We have gone from saying, ‘Let’s just see if we can get the technology to work fundamentally,’ to now where we are focusing on applications." - our CEO, Michael Heltzen, is quoted. The full article is very much worth a read - find it here: https://lnkd.in/d6krxmtk #exozymes #exozyme #biosolutions #biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoid #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech #AI #enzymeengineering #nasdaq #ecofriendly